首页 > 最新文献

American heart journal plus : cardiology research and practice最新文献

英文 中文
Evaluation of coronary microvascular dysfunction using magnetocardiography: A new application to an old technology 利用磁心动图评估冠状动脉微血管功能障碍:古老技术的新应用
IF 1.3 Q3 CARDIAC & CARDIOVASCULAR SYSTEMS Pub Date : 2024-07-10 DOI: 10.1016/j.ahjo.2024.100424
Namrita Ashokprabhu , Khaled Ziada , Edouard Daher , Leslie Cho , Christian W. Schmidt , Yulith Roca , Cassady Palmer , Sukhleen Kaur , Timothy D. Henry , Carl J. Pepine , Odayme Quesada

Background

In patients with angina and non-obstructive coronary artery disease (ANOCA), diagnosis of coronary microvascular dysfunction (CMD) remains an unmet need. Magnetocardiography (MCG), is a rest-based, non-invasive scan that can detect weak electrophysiological changes that occur at the early phase of ischemia.

Objective

This study assessed the ability of MCG to detect CMD in ANOCA patients as compared to reference standard, invasive coronary flow reserve (CFR).

Methods

Patients with ANOCA and invasive coronary physiologic assessment using intracoronary flow measurements with Doppler and thermodilution methods were enrolled. CMD was defined dichotomously as an invasive CFR < 2.0 by Doppler or thermodilution assessment. Noninvasive 36-channel 90-s MCG scan was performed and quantitative assessment of four distinct MCG features was completed. We evaluated the diagnostic performance of 2 or more abnormal MCG features to detect CMD in the overall cohort and performed a subgroup analysis in the subset of patients with Doppler CFR assessment.

Results

Among 79 ANOCA patients, 25 were CMD positive and 54 patients were CMD negative by CFR. Using invasive CFR as reference, MCG had an ROC AUC of 0.66 with a sensitivity of 68 % and specificity of 65 % for the detection of CMD. In the subgroup with Doppler CFR assessment, MCG had an ROC AUC of 0.76 with a sensitivity of 75 % and specificity of 77 %.

Conclusions

In ANOCA patients, MCG demonstrates the ability to detect CMD using a 90-second non-invasive scan without the need for an intravenous stressor or ionizing radiation. Further investigations are needed to validate an MCG-based diagnostic pathway for CMD.

背景在心绞痛和非阻塞性冠状动脉疾病(ANOCA)患者中,冠状动脉微血管功能障碍(CMD)的诊断仍是一项尚未满足的需求。本研究评估了磁共振心动图(MCG)与参考标准--有创冠状动脉血流储备(CFR)--相比,检测 ANOCA 患者 CMD 的能力。多普勒或热稀释法评估的有创 CFR <2.0,即为 CMD。进行了无创 36 通道 90 秒 MCG 扫描,并完成了对四种不同 MCG 特征的定量评估。我们评估了总体队列中 2 个或 2 个以上异常 MCG 特征对检测 CMD 的诊断性能,并对进行了多普勒 CFR 评估的患者子集进行了亚组分析。以有创 CFR 为参照,MCG 的 ROC AUC 为 0.66,对 CMD 检测的灵敏度为 68%,特异度为 65%。结论 在 ANOCA 患者中,MCG 证明了在无需静脉应激物或电离辐射的情况下,通过 90 秒无创扫描检测 CMD 的能力。要验证基于 MCG 的 CMD 诊断路径,还需要进一步的研究。
{"title":"Evaluation of coronary microvascular dysfunction using magnetocardiography: A new application to an old technology","authors":"Namrita Ashokprabhu ,&nbsp;Khaled Ziada ,&nbsp;Edouard Daher ,&nbsp;Leslie Cho ,&nbsp;Christian W. Schmidt ,&nbsp;Yulith Roca ,&nbsp;Cassady Palmer ,&nbsp;Sukhleen Kaur ,&nbsp;Timothy D. Henry ,&nbsp;Carl J. Pepine ,&nbsp;Odayme Quesada","doi":"10.1016/j.ahjo.2024.100424","DOIUrl":"https://doi.org/10.1016/j.ahjo.2024.100424","url":null,"abstract":"<div><h3>Background</h3><p>In patients with angina and non-obstructive coronary artery disease (ANOCA), diagnosis of coronary microvascular dysfunction (CMD) remains an unmet need. Magnetocardiography (MCG), is a rest-based, non-invasive scan that can detect weak electrophysiological changes that occur at the early phase of ischemia.</p></div><div><h3>Objective</h3><p>This study assessed the ability of MCG to detect CMD in ANOCA patients as compared to reference standard, invasive coronary flow reserve (CFR).</p></div><div><h3>Methods</h3><p>Patients with ANOCA and invasive coronary physiologic assessment using intracoronary flow measurements with Doppler and thermodilution methods were enrolled. CMD was defined dichotomously as an invasive CFR &lt; 2.0 by Doppler or thermodilution assessment. Noninvasive 36-channel 90-s MCG scan was performed and quantitative assessment of four distinct MCG features was completed. We evaluated the diagnostic performance of 2 or more abnormal MCG features to detect CMD in the overall cohort and performed a subgroup analysis in the subset of patients with Doppler CFR assessment.</p></div><div><h3>Results</h3><p>Among 79 ANOCA patients, 25 were CMD positive and 54 patients were CMD negative by CFR. Using invasive CFR as reference, MCG had an ROC AUC of 0.66 with a sensitivity of 68 % and specificity of 65 % for the detection of CMD. In the subgroup with Doppler CFR assessment, MCG had an ROC AUC of 0.76 with a sensitivity of 75 % and specificity of 77 %.</p></div><div><h3>Conclusions</h3><p>In ANOCA patients, MCG demonstrates the ability to detect CMD using a 90-second non-invasive scan without the need for an intravenous stressor or ionizing radiation. Further investigations are needed to validate an MCG-based diagnostic pathway for CMD.</p></div>","PeriodicalId":72158,"journal":{"name":"American heart journal plus : cardiology research and practice","volume":"44 ","pages":"Article 100424"},"PeriodicalIF":1.3,"publicationDate":"2024-07-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2666602224000673/pdfft?md5=68a2dc70cbc1a806b2918184b6b3d367&pid=1-s2.0-S2666602224000673-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141593813","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The impact of coronavirus disease 2019 on acute coronary syndrome: Differences between epidemic waves 2019 年冠状病毒疾病对急性冠状动脉综合征的影响:流行病浪潮之间的差异
IF 1.3 Q3 CARDIAC & CARDIOVASCULAR SYSTEMS Pub Date : 2024-07-03 DOI: 10.1016/j.ahjo.2024.100422
Vincenzo Sucato, Giusy Sausa, Grazia Gambino, Alessandro D'Agostino, Salvatore Evola, Giuseppina Novo, Egle Corrado, Alfredo Ruggero Galassi

Introduction

Since the beginning of the COronaVIrus Disease 2019 (COVID-19) pandemic, poor attention has been paid to the indirect effects of the pandemia on cardiovascular health system, in particular in patients with Acute Coronary Syndrome (ACS). The aims of this study is to compare possible epidemiological, clinical and management differences between the four epidemic waves in groups of patients hospitalized for ACS with a view to highlighting the burden of the pandemic on the management of this syndrome.

Materials and methods

In this retrospective observational study we included 98 patients admitted to Coronary Intensive Care Unit (CICU) for ACS between March 2020 and March 2022, who underwent revascularization procedure using percutaneous coronary angioplasty (PCI). The patients examined were divided into four groups representative of the four epidemic waves that affected our country.

Results

The rate of hospitalization for ACS increased progressively to a 178 % increase in the third wave compared to the first (p = 0.003), with an increase of 900 % if we consider only Non-ST-Elevation Myocardial Infarction (NSTEMI) (representing 54 % of the ACS diagnoses of the third group against 14.3 % in the first). Longer door-to-balloon times were recorded in the third wave for the increased presence of NSTEMI. The average hospital stay was lower in the third wave with 5 ± 2 days (p = 0.007) as well as mortality (5.1 % in the third wave; the highest in the fourth wave with 9.5 %).

Conclusions

The study show that the management of ACS suffered most from the indirect effects of the pandemic during the first wave, both because of the unpreparedness of hospital facilities and because of the fear of infection that has dissuaded people from asking for help.

导言自 2019 年 COronaVIrus 病(COVID-19)大流行开始以来,人们很少关注大流行对心血管健康系统的间接影响,尤其是对急性冠状动脉综合征(ACS)患者的影响。本研究的目的是比较四次疫情对急性冠状动脉综合征(ACS)住院患者群体在流行病学、临床和管理方面可能造成的差异,以强调疫情对该综合征管理造成的负担。材料和方法在这项回顾性观察研究中,我们纳入了 2020 年 3 月至 2022 年 3 月期间因急性冠状动脉综合征(ACS)入住冠心病重症监护病房(CICU),并接受经皮冠状动脉血管成形术(PCI)血管重建手术的 98 名患者。受检患者被分为四组,分别代表影响我国的四次流行病浪潮。结果与第一次流行病浪潮相比,第三次流行病浪潮的 ACS 住院率逐步上升,增加了 178%(p = 0.003),如果仅考虑非 ST 段抬高型心肌梗死(NSTEMI),则增加了 900%(占第三组 ACS 诊断的 54%,而第一组为 14.3%)。由于 NSTEMI 的增加,第三组患者的门到气球时间更长。第三组的平均住院时间较短,为 5 ± 2 天(p = 0.007),死亡率也较低(第三组为 5.1%;第四组最高,为 9.5%)。
{"title":"The impact of coronavirus disease 2019 on acute coronary syndrome: Differences between epidemic waves","authors":"Vincenzo Sucato,&nbsp;Giusy Sausa,&nbsp;Grazia Gambino,&nbsp;Alessandro D'Agostino,&nbsp;Salvatore Evola,&nbsp;Giuseppina Novo,&nbsp;Egle Corrado,&nbsp;Alfredo Ruggero Galassi","doi":"10.1016/j.ahjo.2024.100422","DOIUrl":"https://doi.org/10.1016/j.ahjo.2024.100422","url":null,"abstract":"<div><h3>Introduction</h3><p>Since the beginning of the COronaVIrus Disease 2019 (COVID-19) pandemic, poor attention has been paid to the indirect effects of the pandemia on cardiovascular health system, in particular in patients with Acute Coronary Syndrome (ACS). The aims of this study is to compare possible epidemiological, clinical and management differences between the four epidemic waves in groups of patients hospitalized for ACS with a view to highlighting the burden of the pandemic on the management of this syndrome.</p></div><div><h3>Materials and methods</h3><p>In this retrospective observational study we included 98 patients admitted to Coronary Intensive Care Unit (CICU) for ACS between March 2020 and March 2022, who underwent revascularization procedure using percutaneous coronary angioplasty (PCI). The patients examined were divided into four groups representative of the four epidemic waves that affected our country.</p></div><div><h3>Results</h3><p>The rate of hospitalization for ACS increased progressively to a 178 % increase in the third wave compared to the first (<em>p</em> = 0.003), with an increase of 900 % if we consider only Non-ST-Elevation Myocardial Infarction (NSTEMI) (representing 54 % of the ACS diagnoses of the third group against 14.3 % in the first). Longer door-to-balloon times were recorded in the third wave for the increased presence of NSTEMI. The average hospital stay was lower in the third wave with 5 ± 2 days (<em>p</em> = 0.007) as well as mortality (5.1 % in the third wave; the highest in the fourth wave with 9.5 %).</p></div><div><h3>Conclusions</h3><p>The study show that the management of ACS suffered most from the indirect effects of the pandemic during the first wave, both because of the unpreparedness of hospital facilities and because of the fear of infection that has dissuaded people from asking for help.</p></div>","PeriodicalId":72158,"journal":{"name":"American heart journal plus : cardiology research and practice","volume":"44 ","pages":"Article 100422"},"PeriodicalIF":1.3,"publicationDate":"2024-07-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S266660222400065X/pdfft?md5=dbca308cd584ec34fe47bfca389253da&pid=1-s2.0-S266660222400065X-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141593782","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Participation of transgender and gender diverse persons in cardiovascular clinical trials 变性人和不同性别者参与心血管临床试验
IF 1.3 Q3 CARDIAC & CARDIOVASCULAR SYSTEMS Pub Date : 2024-07-03 DOI: 10.1016/j.ahjo.2024.100420
Rodopi Stamatiou , Georgios Kararigas

Study objective

Transgender persons face increased risk in developing cardiovascular diseases due to administration of hormonal therapy used for gender expression, or due to the presence of other risk factors, such as minority stress and difficulty to have full access to health care. Even though the need for gender diversity in research has been identified, the number of clinical trials including transgender persons remains low. The aim of this study was to highlight gaps in inclusion of transgender individuals in cardiovascular clinical research.

Design, setting

A search in the pubmed.com database, as well as in the clinicaltrials.gov repository, was performed with search terms regarding transgender persons and cardiovascular diseases.

Main outcome measure(s)

The inclusion of transgender persons in cardiovascular clinical trials was evaluated.

Results and conclusions

This study revealed that there is only a small number of cardiovascular clinical trials including or studying transgender persons. This finding demonstrates the overall lack of clinical trials regarding cardiovascular health in transgender individuals and is indicative of their under-representation in clinical research.

研究目的变性人因接受用于性别表达的荷尔蒙疗法,或因存在其他风险因素(如少数群体的压力和难以获得全面的医疗保健服务)而面临患心血管疾病的更大风险。尽管研究中对性别多样性的需求已经得到确认,但包括变性人在内的临床试验数量仍然很少。本研究旨在强调将变性人纳入心血管临床研究的差距。设计、设置在pubmed.com数据库和clinicaltrials.gov资料库中进行了搜索,搜索词涉及变性人和心血管疾病。主要结果测量评估了将变性人纳入心血管临床试验的情况。结果和结论本研究显示,只有少数心血管临床试验包括或研究变性人。这一发现表明,有关变性人心血管健康的临床试验总体上比较缺乏,也表明变性人在临床研究中的代表性不足。
{"title":"Participation of transgender and gender diverse persons in cardiovascular clinical trials","authors":"Rodopi Stamatiou ,&nbsp;Georgios Kararigas","doi":"10.1016/j.ahjo.2024.100420","DOIUrl":"https://doi.org/10.1016/j.ahjo.2024.100420","url":null,"abstract":"<div><h3>Study objective</h3><p>Transgender persons face increased risk in developing cardiovascular diseases due to administration of hormonal therapy used for gender expression, or due to the presence of other risk factors, such as minority stress and difficulty to have full access to health care. Even though the need for gender diversity in research has been identified, the number of clinical trials including transgender persons remains low. The aim of this study was to highlight gaps in inclusion of transgender individuals in cardiovascular clinical research.</p></div><div><h3>Design, setting</h3><p>A search in the <span>pubmed.com</span><svg><path></path></svg> database, as well as in the <span>clinicaltrials.gov</span><svg><path></path></svg> repository, was performed with search terms regarding transgender persons and cardiovascular diseases.</p></div><div><h3>Main outcome measure(s)</h3><p>The inclusion of transgender persons in cardiovascular clinical trials was evaluated.</p></div><div><h3>Results and conclusions</h3><p>This study revealed that there is only a small number of cardiovascular clinical trials including or studying transgender persons. This finding demonstrates the overall lack of clinical trials regarding cardiovascular health in transgender individuals and is indicative of their under-representation in clinical research.</p></div>","PeriodicalId":72158,"journal":{"name":"American heart journal plus : cardiology research and practice","volume":"44 ","pages":"Article 100420"},"PeriodicalIF":1.3,"publicationDate":"2024-07-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2666602224000636/pdfft?md5=f12c6a1f53f4d0f3f61777a2d5e91e43&pid=1-s2.0-S2666602224000636-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141541949","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Catheter ablation compared to medical therapy for ventricular tachycardia in sarcoidosis: nationwide outcomes and hospital readmissions 肉样瘤病室性心动过速导管消融与药物治疗的比较:全国范围内的疗效和再住院率
IF 1.3 Q3 CARDIAC & CARDIOVASCULAR SYSTEMS Pub Date : 2024-07-03 DOI: 10.1016/j.ahjo.2024.100421
Michael I. Gurin , Yuhe Xia , Constantine Tarabanis , Randal I. Goldberg , Robert J. Knotts , Robert Donnino , Alex Reyentovich , Scott Bernstein , Lior Jankelson , Alexander Kushnir , Douglas Holmes , Michael Spinelli , David S. Park , Chirag R. Barbhaiya , Larry A. Chinitz , Anthony Aizer

Background

Catheter ablation (CA) for ventricular tachycardia (VT) can be a useful treatment strategy, however, few studies have compared CA to medical therapy (MT) in the sarcoidosis population.

Objective

To assess in-hospital outcomes and unplanned readmissions following CA for VT compared to MT in patients with sarcoidosis.

Methods

Data was obtained from the Nationwide Readmissions Database between 2010 and 2019 to identify patients with sarcoidosis admitted for VT either undergoing CA or MT during elective and non-elective admission. Primary endpoints were a composite endpoint of inpatient mortality, cardiogenic shock, cardiac arrest and 30-day hospital readmissions. Procedural complications at index admission and causes of readmission were also identified.

Results

Among 1581 patients, 1217 with sarcoidosis and VT underwent MT compared to 168 with CA during non-elective admission. 63 patients admitted electively underwent CA compared with 129 managed medically. There was no difference in the composite outcome for patients undergoing catheter ablation or medical therapy during both non-elective (9.0 % vs 12.0 %, p = 0.312) and elective admission (3.2 % vs. 7.8 %, p = 0.343). The most common cause of readmission were ventricular arrhythmias (VA) in both groups, however, those undergoing elective CA were less likely to be readmitted for VA compared to non-elective CA. The most common complication in the CA group was cardiac tamponade (4.8 %).

Conclusion

VT ablation is associated with similar rates of 30-day readmission compared to MT and does not confer increased risk of harm with respect to inpatient mortality, cardiogenic shock or cardiac arrest. Further research is warranted to determine if a subgroup of sarcoidosis patients admitted with VT are better served with an initial conservative management strategy followed by VT ablation.

背景导管消融(CA)治疗室性心动过速(VT)是一种有效的治疗策略,然而,很少有研究对肉样瘤病人群进行CA与药物治疗(MT)的比较。方法从2010年至2019年期间的全国再入院数据库中获取数据,以确定在择期和非择期入院期间因VT接受CA或MT治疗的肉样瘤病患者。主要终点是住院死亡率、心源性休克、心脏骤停和30天再入院率的复合终点。结果在1581名患者中,1217名患有肉样瘤病和VT的患者接受了MT治疗,而168名患者在非择期入院时接受了CA治疗。63名择期入院的患者接受了CA治疗,而129名患者接受了药物治疗。在非择期入院(9.0% 对 12.0%,P = 0.312)和择期入院(3.2% 对 7.8%,P = 0.343)期间接受导管消融或药物治疗的患者的综合结果没有差异。两组患者中最常见的再入院原因都是室性心律失常(VA),但与非选择性CA相比,选择性CA患者因VA再入院的可能性更小。CA组最常见的并发症是心脏填塞(4.8%)。结论与MT相比,VT消融术的30天再入院率相似,不会增加住院患者死亡率、心源性休克或心脏骤停的危害风险。有必要开展进一步研究,以确定在VT消融术后,是否能更好地对因VT入院的肉样瘤病患者进行初步保守治疗。
{"title":"Catheter ablation compared to medical therapy for ventricular tachycardia in sarcoidosis: nationwide outcomes and hospital readmissions","authors":"Michael I. Gurin ,&nbsp;Yuhe Xia ,&nbsp;Constantine Tarabanis ,&nbsp;Randal I. Goldberg ,&nbsp;Robert J. Knotts ,&nbsp;Robert Donnino ,&nbsp;Alex Reyentovich ,&nbsp;Scott Bernstein ,&nbsp;Lior Jankelson ,&nbsp;Alexander Kushnir ,&nbsp;Douglas Holmes ,&nbsp;Michael Spinelli ,&nbsp;David S. Park ,&nbsp;Chirag R. Barbhaiya ,&nbsp;Larry A. Chinitz ,&nbsp;Anthony Aizer","doi":"10.1016/j.ahjo.2024.100421","DOIUrl":"https://doi.org/10.1016/j.ahjo.2024.100421","url":null,"abstract":"<div><h3>Background</h3><p>Catheter ablation (CA) for ventricular tachycardia (VT) can be a useful treatment strategy, however, few studies have compared CA to medical therapy (MT) in the sarcoidosis population.</p></div><div><h3>Objective</h3><p>To assess in-hospital outcomes and unplanned readmissions following CA for VT compared to MT in patients with sarcoidosis.</p></div><div><h3>Methods</h3><p>Data was obtained from the Nationwide Readmissions Database between 2010 and 2019 to identify patients with sarcoidosis admitted for VT either undergoing CA or MT during elective and non-elective admission. Primary endpoints were a composite endpoint of inpatient mortality, cardiogenic shock, cardiac arrest and 30-day hospital readmissions. Procedural complications at index admission and causes of readmission were also identified.</p></div><div><h3>Results</h3><p>Among 1581 patients, 1217 with sarcoidosis and VT underwent MT compared to 168 with CA during non-elective admission. 63 patients admitted electively underwent CA compared with 129 managed medically. There was no difference in the composite outcome for patients undergoing catheter ablation or medical therapy during both non-elective (9.0 % vs 12.0 %, <em>p</em> = 0.312) and elective admission (3.2 % vs. 7.8 %, <em>p</em> = 0.343). The most common cause of readmission were ventricular arrhythmias (VA) in both groups, however, those undergoing elective CA were less likely to be readmitted for VA compared to non-elective CA. The most common complication in the CA group was cardiac tamponade (4.8 %).</p></div><div><h3>Conclusion</h3><p>VT ablation is associated with similar rates of 30-day readmission compared to MT and does not confer increased risk of harm with respect to inpatient mortality, cardiogenic shock or cardiac arrest. Further research is warranted to determine if a subgroup of sarcoidosis patients admitted with VT are better served with an initial conservative management strategy followed by VT ablation.</p></div>","PeriodicalId":72158,"journal":{"name":"American heart journal plus : cardiology research and practice","volume":"44 ","pages":"Article 100421"},"PeriodicalIF":1.3,"publicationDate":"2024-07-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2666602224000648/pdfft?md5=adee334be461cc6e02a7a9bcd943a566&pid=1-s2.0-S2666602224000648-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141594885","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
In memoriam 纪念
IF 1.3 Q3 CARDIAC & CARDIOVASCULAR SYSTEMS Pub Date : 2024-07-01 DOI: 10.1016/j.ahjo.2024.100415
{"title":"In memoriam","authors":"","doi":"10.1016/j.ahjo.2024.100415","DOIUrl":"10.1016/j.ahjo.2024.100415","url":null,"abstract":"","PeriodicalId":72158,"journal":{"name":"American heart journal plus : cardiology research and practice","volume":"44 ","pages":"Article 100415"},"PeriodicalIF":1.3,"publicationDate":"2024-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2666602224000582/pdfft?md5=b482b69f6625f820440c904953d96342&pid=1-s2.0-S2666602224000582-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141636543","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Exploring the underlying molecular mechanisms of acute myocardial infarction after SARS-CoV-2 infection 探索 SARS-CoV-2 感染后急性心肌梗死的分子机制
IF 1.3 Q3 CARDIAC & CARDIOVASCULAR SYSTEMS Pub Date : 2024-06-28 DOI: 10.1016/j.ahjo.2024.100417
Enrui Xie , Xiaotao Shen , Yee Hui Yeo , Zixuan Xing , Joseph E. Ebinger , Yixuan Duan , Yue Zhang , Susan Cheng , Fanpu Ji , Jie Deng

An increase in acute myocardial infarction (AMI)-related deaths has been reported during the COVID-19 pandemic. Despite evidence suggesting the association between severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and AMI, the underlying mechanisms remain unclear. Here, we integrated mRNA and microRNA expression profiles related to SARS-CoV-2 infection and AMI from public databases. We then performed transcriptomic analysis using bioinformatics and systems biology approaches to explore the potential molecular mechanisms of SARS-CoV-2 infection affects AMI. First, twenty-one common differentially expressed genes (DEGs) were identified from SARS-CoV-2 infection and AMI patients in endothelial cells datasets and then we performed functional analysis to predict the roles of these DEGs. The functional analysis emphasized that the endothelial cell response to cytokine stimulus due to excessive inflammation was essential in these two diseases. Importantly, the tumor necrosis factor and interleukin-17 signaling pathways appeared to be integral factors in this mechanism. Interestingly, most of these common genes were also upregulated in transcriptomic datasets of SARS-CoV-2-infected cardiomyocytes, suggesting that these genes may be shared in cardiac- and vascular-related injuries. We subsequently built a protein-protein interaction network and extracted hub genes and essential modules from this network. At the transcriptional and post-transcriptional levels, regulatory networks with common DEGs were also constructed, and some key regulator signatures were further identified and validated. In summary, our research revealed that a highly activated inflammatory response in patients with COVID-19 might be a crucial factor for susceptibility to AMI and we identified some candidate genes and regulators that could be used as biomarkers or potential therapeutic targets.

据报道,在 COVID-19 大流行期间,与急性心肌梗死(AMI)相关的死亡人数有所增加。尽管有证据表明严重急性呼吸系统综合征冠状病毒 2(SARS-CoV-2)感染与急性心肌梗死之间存在关联,但其潜在机制仍不清楚。在此,我们整合了公共数据库中与 SARS-CoV-2 感染和 AMI 相关的 mRNA 和 microRNA 表达谱。然后,我们利用生物信息学和系统生物学方法进行了转录组分析,以探索 SARS-CoV-2 感染影响 AMI 的潜在分子机制。首先,我们从SARS-CoV-2感染和AMI患者的内皮细胞数据集中发现了21个常见的差异表达基因(DEGs),然后进行了功能分析以预测这些DEGs的作用。功能分析结果表明,在这两种疾病中,内皮细胞对过度炎症导致的细胞因子刺激的反应至关重要。重要的是,肿瘤坏死因子和白细胞介素-17 信号通路似乎是这一机制中不可或缺的因素。有趣的是,在 SARS-CoV-2 感染的心肌细胞的转录组数据集中,这些常见基因中的大多数也出现了上调,这表明这些基因可能在心脏和血管相关损伤中具有共通性。随后,我们建立了一个蛋白质-蛋白质相互作用网络,并从中提取了枢纽基因和重要模块。在转录和转录后水平,我们还构建了具有共同 DEGs 的调控网络,并进一步鉴定和验证了一些关键调控因子特征。总之,我们的研究揭示了 COVID-19 患者高度激活的炎症反应可能是导致 AMI 易感性的关键因素,我们还发现了一些候选基因和调控因子,它们可用作生物标记物或潜在的治疗靶点。
{"title":"Exploring the underlying molecular mechanisms of acute myocardial infarction after SARS-CoV-2 infection","authors":"Enrui Xie ,&nbsp;Xiaotao Shen ,&nbsp;Yee Hui Yeo ,&nbsp;Zixuan Xing ,&nbsp;Joseph E. Ebinger ,&nbsp;Yixuan Duan ,&nbsp;Yue Zhang ,&nbsp;Susan Cheng ,&nbsp;Fanpu Ji ,&nbsp;Jie Deng","doi":"10.1016/j.ahjo.2024.100417","DOIUrl":"https://doi.org/10.1016/j.ahjo.2024.100417","url":null,"abstract":"<div><p>An increase in acute myocardial infarction (AMI)-related deaths has been reported during the COVID-19 pandemic. Despite evidence suggesting the association between severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and AMI, the underlying mechanisms remain unclear. Here, we integrated mRNA and microRNA expression profiles related to SARS-CoV-2 infection and AMI from public databases. We then performed transcriptomic analysis using bioinformatics and systems biology approaches to explore the potential molecular mechanisms of SARS-CoV-2 infection affects AMI. First, twenty-one common differentially expressed genes (DEGs) were identified from SARS-CoV-2 infection and AMI patients in endothelial cells datasets and then we performed functional analysis to predict the roles of these DEGs. The functional analysis emphasized that the endothelial cell response to cytokine stimulus due to excessive inflammation was essential in these two diseases. Importantly, the tumor necrosis factor and interleukin-17 signaling pathways appeared to be integral factors in this mechanism. Interestingly, most of these common genes were also upregulated in transcriptomic datasets of SARS-CoV-2-infected cardiomyocytes, suggesting that these genes may be shared in cardiac- and vascular-related injuries. We subsequently built a protein-protein interaction network and extracted hub genes and essential modules from this network. At the transcriptional and post-transcriptional levels, regulatory networks with common DEGs were also constructed, and some key regulator signatures were further identified and validated. In summary, our research revealed that a highly activated inflammatory response in patients with COVID-19 might be a crucial factor for susceptibility to AMI and we identified some candidate genes and regulators that could be used as biomarkers or potential therapeutic targets.</p></div>","PeriodicalId":72158,"journal":{"name":"American heart journal plus : cardiology research and practice","volume":"44 ","pages":"Article 100417"},"PeriodicalIF":1.3,"publicationDate":"2024-06-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2666602224000600/pdfft?md5=9570bf66bd1f55b63e86eddfc1c4fa3c&pid=1-s2.0-S2666602224000600-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141483479","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Teaching gender medicine can enhance the quality of healthcare 性别医学教学可提高医疗质量
IF 1.3 Q3 CARDIAC & CARDIOVASCULAR SYSTEMS Pub Date : 2024-06-25 DOI: 10.1016/j.ahjo.2024.100418
Anna Vittoria Mattioli , Valentina Bucciarelli , Sabina Gallina

Teaching gender and sex differences is fundamental in medical classes because it has a strong impact in reducing disparity in treatment, in defining effective and personalized therapies that respect the different physiology and pathophysiology of women. Furthermore, it is the prerequisite for the pharmacoequity.

在医学课程中讲授性别和性别差异是非常重要的,因为这对减少治疗中的差异、确定有效的个性化疗法、尊重女性不同的生理和病理生理学有很大的影响。此外,这也是实现药剂公平的前提条件。
{"title":"Teaching gender medicine can enhance the quality of healthcare","authors":"Anna Vittoria Mattioli ,&nbsp;Valentina Bucciarelli ,&nbsp;Sabina Gallina","doi":"10.1016/j.ahjo.2024.100418","DOIUrl":"https://doi.org/10.1016/j.ahjo.2024.100418","url":null,"abstract":"<div><p>Teaching gender and sex differences is fundamental in medical classes because it has a strong impact in reducing disparity in treatment, in defining effective and personalized therapies that respect the different physiology and pathophysiology of women. Furthermore, it is the prerequisite for the pharmacoequity.</p></div>","PeriodicalId":72158,"journal":{"name":"American heart journal plus : cardiology research and practice","volume":"44 ","pages":"Article 100418"},"PeriodicalIF":1.3,"publicationDate":"2024-06-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2666602224000612/pdfft?md5=19a5a4e04030ecbef15bc58b658d6e5a&pid=1-s2.0-S2666602224000612-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141478694","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Safety and efficacy of aminophylline in the prevention of bradyarrhythmia during coronary atherectomy 氨茶碱在冠状动脉粥样硬化切除术中预防缓慢性心律失常的安全性和有效性
IF 1.3 Q3 CARDIAC & CARDIOVASCULAR SYSTEMS Pub Date : 2024-06-25 DOI: 10.1016/j.ahjo.2024.100419
Asaad Nakhle , Katherine J. Kunkel , Obadah Aqtash , Samer Zakhour , Lizbeth Brice , Jelena Arnautovic , Parth Desai , Milan Kaushik , Keith Ferdinand , Khaldoon Alaswad , Mir Babar Basir

Coronary calcified lesions are commonly encountered and coronary atherectomy is commonly used for lesion modification during percutaneous coronary interventions (PCI). The release of adenosine during atherectomy can result in bradyarrhythmias and aminophylline is commonly used to prevent this reaction. We identified 138 patients to evaluate the safety and efficacy of intravenous (IV) aminophylline administration prior to coronary atherectomy. A total of 159 calcified lesions were treated, and the atherectomy device was orbital atherectomy, rotational atherectomy, and both in 52 %, 42 %, and 6 %; respectively. After administration of aminophylline, 4.3 % of patients required intraprocedural insertion of a transvenous pacer (TVP), and 18.1 % of patients required administration of IV atropine. Technical success was achieved in 98.6 % of patients, and no adverse reactions to aminophylline were reported. All patients survived to discharge. In conclusion, aminophylline administration prior to coronary atherectomy was safe and effective. No adverse effects of aminophylline were seen, and the rate of bailout TVP placement was low.

冠状动脉钙化病变很常见,冠状动脉粥样硬化切除术通常用于经皮冠状动脉介入治疗(PCI)中的病变改造。动脉粥样硬化切除术中释放的腺苷可导致心动过缓,而氨茶碱通常用于预防这种反应。我们确定了 138 名患者,以评估冠状动脉粥样硬化切除术前静脉注射氨茶碱的安全性和有效性。我们共治疗了 159 个钙化病灶,采用轨道式粥样斑块切除术、旋转式粥样斑块切除术或两者兼用的比例分别为 52%、42% 和 6%。使用氨茶碱后,4.3%的患者需要在术中插入经静脉起搏器(TVP),18.1%的患者需要静脉注射阿托品。98.6%的患者获得了技术上的成功,未报告氨茶碱的不良反应。所有患者均顺利出院。总之,在冠状动脉粥样硬化切除术前使用氨茶碱是安全有效的。氨茶碱未见不良反应,保外TVP置入率较低。
{"title":"Safety and efficacy of aminophylline in the prevention of bradyarrhythmia during coronary atherectomy","authors":"Asaad Nakhle ,&nbsp;Katherine J. Kunkel ,&nbsp;Obadah Aqtash ,&nbsp;Samer Zakhour ,&nbsp;Lizbeth Brice ,&nbsp;Jelena Arnautovic ,&nbsp;Parth Desai ,&nbsp;Milan Kaushik ,&nbsp;Keith Ferdinand ,&nbsp;Khaldoon Alaswad ,&nbsp;Mir Babar Basir","doi":"10.1016/j.ahjo.2024.100419","DOIUrl":"10.1016/j.ahjo.2024.100419","url":null,"abstract":"<div><p>Coronary calcified lesions are commonly encountered and coronary atherectomy is commonly used for lesion modification during percutaneous coronary interventions (PCI). The release of adenosine during atherectomy can result in bradyarrhythmias and aminophylline is commonly used to prevent this reaction. We identified 138 patients to evaluate the safety and efficacy of intravenous (IV) aminophylline administration prior to coronary atherectomy. A total of 159 calcified lesions were treated, and the atherectomy device was orbital atherectomy, rotational atherectomy, and both in 52 %, 42 %, and 6 %; respectively. After administration of aminophylline, 4.3 % of patients required intraprocedural insertion of a transvenous pacer (TVP), and 18.1 % of patients required administration of IV atropine. Technical success was achieved in 98.6 % of patients, and no adverse reactions to aminophylline were reported. All patients survived to discharge. In conclusion, aminophylline administration prior to coronary atherectomy was safe and effective. No adverse effects of aminophylline were seen, and the rate of bailout TVP placement was low.</p></div>","PeriodicalId":72158,"journal":{"name":"American heart journal plus : cardiology research and practice","volume":"44 ","pages":"Article 100419"},"PeriodicalIF":1.3,"publicationDate":"2024-06-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2666602224000624/pdfft?md5=b0308a99c9f3848af18612ff0cb3615d&pid=1-s2.0-S2666602224000624-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141636542","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The role of p130Cas/BCAR1 adaptor protein in the pathogenesis of cardiovascular diseases: A literature review p130Cas/BCAR1 适应蛋白在心血管疾病发病机制中的作用:文献综述
IF 1.3 Q3 CARDIAC & CARDIOVASCULAR SYSTEMS Pub Date : 2024-06-25 DOI: 10.1016/j.ahjo.2024.100416
Ghazal Ghasempour Dabaghi , Mehrdad Rabiee Rad , Reza Amani-Beni , Bahar Darouei

Breast cancer anti-estrogen resistance-1 (p130Cas/BCAR1) is an adaptor protein of the cas(Cas) family. This protein regulates multiple complex pathways in different organs including bones, pancreas, and immune and cardiovascular systems. Although previous research well demonstrated the role of p130Cas/BCAR1 in different diseases especially cancers, a precise review study on the various effects of p130Cas/BCAR1 on cardiovascular diseases is missing. In this study, we reviewed mechanisms of action for p130Cas/BCAR1 impact, on cardiac embryonic development defects, hypertrophy and remodeling, pulmonary artery hypertension (PAH), and atherosclerosis. Also, we suggest feature direction for research and potential therapeutic implications. This study showed that p130Cas/BCAR1 can affect cardiovascular diseases in various mechanisms including actin stress fiber formation, attachment to focal adhesion kinase (FAK) and angiotensin II (Ang II), generation of reactive oxygen species (ROS), and growth factor signaling through amplifying receptor tyrosine kinase (RTKs).

乳腺癌抗雌激素-1(p130Cas/BCAR1)是 cas(Cas)家族的一种适配蛋白。该蛋白调节不同器官中的多种复杂通路,包括骨骼、胰腺、免疫和心血管系统。尽管之前的研究充分证明了 p130Cas/BCAR1 在不同疾病尤其是癌症中的作用,但目前还没有关于 p130Cas/BCAR1 对心血管疾病的各种影响的精确综述研究。在本研究中,我们回顾了 p130Cas/BCAR1 对心脏胚胎发育缺陷、肥大和重塑、肺动脉高压(PAH)和动脉粥样硬化的影响机制。同时,我们还提出了特色研究方向和潜在的治疗意义。这项研究表明,p130Cas/BCAR1 可通过多种机制影响心血管疾病,包括肌动蛋白应力纤维的形成、与病灶粘附激酶(FAK)和血管紧张素 II(Ang II)的粘附、活性氧(ROS)的生成以及通过放大受体酪氨酸激酶(RTKs)的生长因子信号转导。
{"title":"The role of p130Cas/BCAR1 adaptor protein in the pathogenesis of cardiovascular diseases: A literature review","authors":"Ghazal Ghasempour Dabaghi ,&nbsp;Mehrdad Rabiee Rad ,&nbsp;Reza Amani-Beni ,&nbsp;Bahar Darouei","doi":"10.1016/j.ahjo.2024.100416","DOIUrl":"https://doi.org/10.1016/j.ahjo.2024.100416","url":null,"abstract":"<div><p>Breast cancer anti-estrogen resistance-1 (p130Cas/BCAR1) is an adaptor protein of the cas(Cas) family. This protein regulates multiple complex pathways in different organs including bones, pancreas, and immune and cardiovascular systems. Although previous research well demonstrated the role of p130Cas/BCAR1 in different diseases especially cancers, a precise review study on the various effects of p130Cas/BCAR1 on cardiovascular diseases is missing. In this study, we reviewed mechanisms of action for p130Cas/BCAR1 impact, on cardiac embryonic development defects, hypertrophy and remodeling, pulmonary artery hypertension (PAH), and atherosclerosis. Also, we suggest feature direction for research and potential therapeutic implications. This study showed that p130Cas/BCAR1 can affect cardiovascular diseases in various mechanisms including actin stress fiber formation, attachment to focal adhesion kinase (FAK) and angiotensin II (Ang II), generation of reactive oxygen species (ROS), and growth factor signaling through amplifying receptor tyrosine kinase (RTKs).</p></div>","PeriodicalId":72158,"journal":{"name":"American heart journal plus : cardiology research and practice","volume":"44 ","pages":"Article 100416"},"PeriodicalIF":1.3,"publicationDate":"2024-06-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2666602224000594/pdfft?md5=471cf0f54d8ed646c8163c00229e1fd3&pid=1-s2.0-S2666602224000594-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141486417","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The barbershop paradigm: Community engagement for cardiovascular prevention 理发店模式社区参与心血管疾病预防
IF 1.3 Q3 CARDIAC & CARDIOVASCULAR SYSTEMS Pub Date : 2024-06-20 DOI: 10.1016/j.ahjo.2024.100414
Ruxandra Ionescu , Jared W. Magnani

Barbershops and beauty salons provide community-specific opportunities to engage in cardiovascular disease screening and prevention. This editorial articulates the advantages of what is termed the “barbershop paradigm,” the community-engaged endeavor that leverages familiarity, trust, and stakeholder engagement to advance cardiovascular health. The authors summarize the neighborhood-based factors that contribute to cardiovascular health, and then identify the strategies implemented by ShopTalk and their specific advantages.

理发店和美容院为社区提供了参与心血管疾病筛查和预防的特定机会。这篇社论阐述了所谓 "理发店范式 "的优势,即社区参与的努力,利用熟悉、信任和利益相关者的参与来促进心血管健康。作者总结了促进心血管健康的邻里因素,然后指出了 ShopTalk 实施的策略及其具体优势。
{"title":"The barbershop paradigm: Community engagement for cardiovascular prevention","authors":"Ruxandra Ionescu ,&nbsp;Jared W. Magnani","doi":"10.1016/j.ahjo.2024.100414","DOIUrl":"https://doi.org/10.1016/j.ahjo.2024.100414","url":null,"abstract":"<div><p>Barbershops and beauty salons provide community-specific opportunities to engage in cardiovascular disease screening and prevention. This editorial articulates the advantages of what is termed the “barbershop paradigm,” the community-engaged endeavor that leverages familiarity, trust, and stakeholder engagement to advance cardiovascular health. The authors summarize the neighborhood-based factors that contribute to cardiovascular health, and then identify the strategies implemented by <em>ShopTalk</em> and their specific advantages.</p></div>","PeriodicalId":72158,"journal":{"name":"American heart journal plus : cardiology research and practice","volume":"44 ","pages":"Article 100414"},"PeriodicalIF":1.3,"publicationDate":"2024-06-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2666602224000570/pdfft?md5=166459f8d7d5984756045aa92a6e8fdd&pid=1-s2.0-S2666602224000570-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141434998","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
American heart journal plus : cardiology research and practice
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1